Double maintains 2 strategies that include ARWR - Arrowhead Pharmaceuticals, Inc.
Current Value
$21.231 Year Return
Current Value
$21.231 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -0.03% | $84.10B | +13.51% | 4.44% |
LNG | -0.06% | $52.57B | +42.65% | 0.76% |
SRRK | 0.08% | $4.25B | +204.49% | 0.00% |
E | -0.13% | $45.14B | -11.17% | 7.43% |
NEUE | 0.14% | $60.67M | -50.84% | 0.00% |
SYPR | -0.22% | $51.68M | +3.94% | 0.00% |
SHEL | 0.27% | $202.29B | +6.67% | 4.14% |
OCFT | -0.31% | $102.29M | +4.91% | 0.00% |
LTM | 0.32% | $8.46B | -100.00% | <0.01% |
PDCO | 0.33% | $2.73B | +1.85% | 2.52% |
STNG | -0.34% | $2.54B | -30.59% | 3.34% |
MELI | -0.36% | $92.71B | +5.17% | 0.00% |
HRTG | -0.48% | $346.12M | +81.94% | 0.00% |
FENG | 0.50% | $12.11M | +51.34% | 0.00% |
CREG | 0.53% | $6.34M | -59.28% | 0.00% |
ACIC | 0.57% | $588.10M | +9.37% | 0.00% |
BTCT | 0.59% | $37.49M | +84.20% | 0.00% |
TBRG | 0.59% | $343.73M | +125.78% | 0.00% |
MNR | 0.62% | $1.89B | +1.33% | 17.33% |
KOF | -0.79% | $3.94B | -17.56% | 5.44% |
Finnhub
Arrowhead Pharmaceuticals, Inc. today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first...
Finnhub
PASADENA - Arrowhead Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational plozasiran for the treatment of...
Finnhub
By Connor Hart Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a...
Yahoo
The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for patients living with obesity.
Yahoo
PASADENA, Calif., December 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a k
Finnhub
PASADENA - Arrowhead Pharmaceuticals, Inc. today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTLA | 47.70% | $1.15B | -55.00% | 0.00% |
CRNX | 46.86% | $3.64B | +5.23% | 0.00% |
FATE | 43.65% | $152.62M | -70.61% | 0.00% |
BEAM | 43.31% | $2.18B | +5.50% | 0.00% |
VSH | 41.42% | $2.33B | -22.89% | 2.34% |
DNLI | 41.06% | $3.35B | +35.35% | 0.00% |
IONS | 41.01% | $5.44B | -33.19% | 0.00% |
PLRX | 40.99% | $677.91M | -35.27% | 0.00% |
PGEN | 40.76% | $392.44M | -5.63% | 0.00% |
CRSP | 39.67% | $3.78B | -29.65% | 0.00% |
EDIT | 39.29% | $116.39M | -81.88% | 0.00% |
RGNX | 39.06% | $393.88M | -40.05% | 0.00% |
MGTX | 39.01% | $474.39M | -9.67% | 0.00% |
CSGP | 38.98% | $30.49B | -12.09% | 0.00% |
VYGR | 38.45% | $302.08M | -27.33% | 0.00% |
YMAB | 38.31% | $281.28M | -40.42% | 0.00% |
RCKT | 37.79% | $1.18B | -61.03% | 0.00% |
OCUL | 37.68% | $1.25B | +86.01% | 0.00% |
IDYA | 37.42% | $2.01B | -45.20% | 0.00% |
RARE | 36.93% | $4.14B | -0.88% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYCN | -9.83% | $7.90M | -3.80% | 0.00% |
PRPO | -9.42% | $9.58M | +2.25% | 0.00% |
HUSA | -9.25% | $22.12M | +1.20% | 0.00% |
BALY | -6.32% | $734.04M | +57.64% | 0.00% |
GAN | -5.66% | $85.22M | +19.87% | 0.00% |
VHC | -5.04% | $33.26M | +45.99% | 0.00% |
SAM | -4.80% | $2.81B | -31.39% | 0.00% |
QNTM | -4.60% | $6.33M | -93.83% | 0.00% |
TTE | -4.52% | $133.98B | -9.49% | 5.65% |
CCRN | -4.39% | $589.06M | -17.08% | 0.00% |
SYM | -4.37% | $3.57B | -17.26% | 0.00% |
PHI | -4.27% | $4.89B | -0.04% | 7.54% |
CMTL | -4.04% | $71.18M | -66.39% | 0.00% |
IMRN | -3.96% | $11.97M | +10.81% | 0.00% |
TCTM | -3.59% | $2.49M | -72.13% | 0.00% |
CBOE | -3.46% | $21.11B | +6.85% | 1.18% |
K | -3.19% | $28.19B | +49.68% | 2.77% |
FRO | -3.16% | $3.75B | -22.60% | 11.62% |
NHTC | -3.05% | $59.41M | -17.44% | 15.47% |
KR | -2.80% | $42.38B | +26.15% | 2.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 59.66% | $69.64M | 0.5% |
XBI | 59.35% | $6.27B | 0.35% |
IBB | 56.83% | $6.39B | 0.45% |
BBH | 51.24% | $399.71M | 0.35% |
PBE | 51.12% | $254.98M | 0.58% |
FBT | 50.24% | $1.20B | 0.56% |
PTH | 49.80% | $123.48M | 0.6% |
XPH | 49.17% | $167.55M | 0.35% |
PINK | 47.72% | $142.14M | 0.5% |
ARKG | 46.33% | $1.21B | 0.75% |
RSPA | 45.43% | $275.22M | 0% |
FHLC | 43.86% | $2.70B | 0.084% |
VHT | 43.62% | $16.72B | 0.1% |
IWC | 43.37% | $982.44M | 0.6% |
IWO | 42.97% | $13.09B | 0.24% |
HYDB | 42.78% | $1.21B | 0.35% |
JNK | 42.43% | $7.69B | 0.4% |
VTWO | 42.31% | $12.78B | 0.1% |
IWM | 42.28% | $73.87B | 0.19% |
NUHY | 42.24% | $93.78M | 0.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | -0.02% | $148.70M | 0.23% |
DBB | -0.13% | $111.87M | 0.77% |
GCC | -0.31% | $140.48M | 0.55% |
SGOV | 0.36% | $31.97B | 0.09% |
BOXX | -0.59% | $4.86B | 0.1949% |
MINT | -0.85% | $12.26B | 0.35% |
XHLF | -1.18% | $955.89M | 0.03% |
VRIG | 1.88% | $1.21B | 0.3% |
BILZ | -1.89% | $631.56M | 0.14% |
GBIL | 2.06% | $5.80B | 0.12% |
EQLS | -2.10% | $9.58M | 1% |
MEAR | 2.56% | $771.37M | 0.25% |
SHYD | -2.96% | $312.73M | 0.35% |
ULST | 3.36% | $564.88M | 0.2% |
TBIL | -3.47% | $4.85B | 0.15% |
BCD | -3.55% | $251.64M | 0.3% |
TBLL | -3.66% | $1.98B | 0.08% |
CORN | -3.79% | $66.56M | 0.2% |
CLOI | 3.94% | $816.76M | 0.4% |
DUSB | -4.05% | $957.96M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -25.03% | $195.31M | 0.85% |
USDU | -18.65% | $397.66M | 0.5% |
UUP | -17.33% | $634.18M | 0.77% |
CTA | -14.79% | $569.44M | 0.76% |
TPMN | -14.29% | $34.23M | 0.65% |
WEAT | -12.72% | $123.99M | 0.28% |
TAIL | -12.51% | $64.78M | 0.59% |
DBE | -11.54% | $50.17M | 0.77% |
UNG | -9.28% | $664.75M | 1.06% |
DBA | -8.74% | $828.49M | 0.93% |
COMT | -8.48% | $715.33M | 0.48% |
PDBC | -8.22% | $4.44B | 0.59% |
USCI | -7.71% | $204.49M | 1.07% |
GSG | -7.52% | $1.06B | 0.75% |
DBO | -7.48% | $208.65M | 0.77% |
DBC | -6.79% | $1.38B | 0.87% |
FTGC | -5.46% | $2.39B | 1.02% |
CMDY | -4.83% | $296.68M | 0.28% |
BCI | -4.14% | $1.38B | 0.26% |
KMLM | -4.12% | $326.67M | 0.9% |